Department of Neurology, UT Southwestern Medical Center, Dallas, Texas, USA.
Headache. 2022 Oct;62(9):1227-1230. doi: 10.1111/head.14367. Epub 2022 Jul 19.
To demonstrate effect of lacosamide monotherapy in three patients with refractory facial pain of various etiologies.
Many medications used to treat trigeminal neuralgia and other facial pain, including first- and second-generation anticonvulsants, are often ineffective or have intolerable side-effects. Lacosamide, a third-generation anticonvulsant, has fewer side-effects and is a potential treatment of facial pain.
Retrospective review of three patients treated with lacosamide for facial pain.
The etiologies of the facial pain were idiopathic trigeminal neuralgia (TN), TN secondary to a mass, and persistent idiopathic facial pain. Treatment with lacosamide led to significant improvement in pain in all three patients. Lacosamide was well tolerated without any reported side-effects.
Lacosamide effectively relieved idiopathic and secondary facial pain in three previously refractory patients. It may be effective for the treatment of refractory facial pain and could be considered as an alternative treatment for patients who do not respond or tolerate standard treatments for facial pain.
展示拉科酰胺单药治疗三种不同病因难治性面痛患者的效果。
许多用于治疗三叉神经痛和其他面痛的药物，包括第一代和第二代抗惊厥药，往往无效或有无法耐受的副作用。拉科酰胺，一种第三代抗惊厥药，副作用较少，是面痛的潜在治疗药物。
回顾性分析 3 例拉科酰胺治疗面痛的患者。
面痛的病因分别为特发性三叉神经痛（TN）、TN 继发于肿块和持续性特发性面痛。拉科酰胺治疗使所有 3 例患者的疼痛均显著改善。拉科酰胺耐受良好，无任何不良反应报告。
拉科酰胺有效地缓解了 3 例以前难治性患者的特发性和继发性面痛。它可能对面痛的治疗有效，并可考虑作为对标准面痛治疗无反应或不耐受的患者的替代治疗。
